secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2026-01-15T23:59:59+00:00
Accession:  0000947871-26-000037
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific to acquire Penumbra for $374 cash or 3.8721 BSX shares per share (73.26% cash/26.74% stock mix)
--------------------------------------------------------------------------------

- Penumbra shareholders elect cash ($374/share) or stock (3.8721 BSX shares/share); proration targets 73.26% cash, 26.74% stock.
- Penumbra termination fee $525M if superior proposal accepted; BSX pays $900M if regulatory blocks after approval.
- Closing conditions include Penumbra stockholder vote, HSR clearance, S-4 effectiveness, and no material adverse effect.
- Outstanding Penumbra options and RSUs convert to cash/BSX stock based on formulas; certain RSUs assumed by BSX.
- Transaction expected to close in H1 2026, subject to conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000094787126000037/0000947871-26-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000094787126000037/ss5822815_8k.htm
  HTML page:      https://secwatch.observer/filing/0000947871-26-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer